TNB Financial Has $384,000 Holdings in Danaher Co. (DHR)

TNB Financial decreased its position in shares of Danaher Co. (NYSE:DHR) by 27.8% in the 4th quarter, Holdings Channel reports. The firm owned 4,136 shares of the conglomerate’s stock after selling 1,593 shares during the quarter. TNB Financial’s holdings in Danaher were worth $384,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Point72 Asset Management L.P. increased its stake in shares of Danaher by 276.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after acquiring an additional 1,929,751 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Danaher by 16,410.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock valued at $125,395,000 after acquiring an additional 1,476,901 shares in the last quarter. Findlay Park Partners LLP increased its stake in shares of Danaher by 52.9% in the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock valued at $353,186,000 after acquiring an additional 1,425,000 shares in the last quarter. Koch Industries Inc. increased its stake in shares of Danaher by 29,127.3% in the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock valued at $1,388,000 after acquiring an additional 1,399,859 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Danaher by 86.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock valued at $256,136,000 after acquiring an additional 1,393,165 shares in the last quarter. Hedge funds and other institutional investors own 76.19% of the company’s stock.

Danaher Co. (NYSE DHR) opened at $95.25 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market cap of $67,605.03, a price-to-earnings ratio of 24.08, a price-to-earnings-growth ratio of 2.04 and a beta of 1.04. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $104.82.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.03. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.05 EPS. sell-side analysts anticipate that Danaher Co. will post 4.37 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were issued a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date was Thursday, December 28th. Danaher’s dividend payout ratio is 15.86%.

Several research firms recently issued reports on DHR. Stifel Nicolaus lifted their price target on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Royal Bank of Canada reissued a “hold” rating and issued a $98.00 price target on shares of Danaher in a research report on Wednesday, January 31st. Cowen reissued a “buy” rating and issued a $110.00 price target on shares of Danaher in a research report on Tuesday, January 30th. Credit Suisse Group lifted their price target on shares of Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, Argus lifted their price target on shares of Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Danaher currently has a consensus rating of “Buy” and a consensus target price of $100.13.

In other Danaher news, SVP Daniel Raskas sold 37,870 shares of Danaher stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Angela S. Lalor sold 42,988 shares of Danaher stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the transaction, the senior vice president now directly owns 82,008 shares in the company, valued at $8,388,598.32. The disclosure for this sale can be found here. Insiders have sold a total of 274,913 shares of company stock worth $27,729,293 over the last ninety days. Insiders own 12.20% of the company’s stock.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/08/tnb-financial-has-384000-holdings-in-danaher-co-dhr.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply